I

n a setback for PTC Therapeutics, the Washington State Drug Utilization Review Board has decided to recommend another medicine for treating Duchenne muscular dystrophy rather than a similar but highly controversial drug that the company recently agreed to purchase.

The board on Wednesday endorsed a policy by the Washington State Health Care Authority, which administers the state Medicaid program, that prednisone is the “lower cost, equally effective alternative” to Emflaza, the drug that PTC agreed to buy for at least $140 million last month from Marathon Pharmaceuticals.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.